Cargando…

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours

OBJECTIVES: The relative contributions of inflammatory signalling and sequential oncogenic dysregulation driving liver cancer pathogenesis remain incompletely understood. Lymphotoxin-β receptor (LTβR) signalling is critically involved in hepatitis and liver tumorigenesis. Therefore, we explored the...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarzello, Anthony J, Jiang, Qun, Back, Timothy, Dang, Hien, Hodge, Deborah, Hanson, Charlotte, Subleski, Jeffrey, Weiss, Jonathan M, Stauffer, Jimmy K, Chaisaingmongkol, Jitti, Rabibhadana, Siritida, Ruchirawat, Mathuros, Ortaldo, John, Wang, Xin Wei, Norris, Paula S, Ware, Carl F, Wiltrout, Robert H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036232/
https://www.ncbi.nlm.nih.gov/pubmed/26206664
http://dx.doi.org/10.1136/gutjnl-2014-308810
_version_ 1782455523576119296
author Scarzello, Anthony J
Jiang, Qun
Back, Timothy
Dang, Hien
Hodge, Deborah
Hanson, Charlotte
Subleski, Jeffrey
Weiss, Jonathan M
Stauffer, Jimmy K
Chaisaingmongkol, Jitti
Rabibhadana, Siritida
Ruchirawat, Mathuros
Ortaldo, John
Wang, Xin Wei
Norris, Paula S
Ware, Carl F
Wiltrout, Robert H
author_facet Scarzello, Anthony J
Jiang, Qun
Back, Timothy
Dang, Hien
Hodge, Deborah
Hanson, Charlotte
Subleski, Jeffrey
Weiss, Jonathan M
Stauffer, Jimmy K
Chaisaingmongkol, Jitti
Rabibhadana, Siritida
Ruchirawat, Mathuros
Ortaldo, John
Wang, Xin Wei
Norris, Paula S
Ware, Carl F
Wiltrout, Robert H
author_sort Scarzello, Anthony J
collection PubMed
description OBJECTIVES: The relative contributions of inflammatory signalling and sequential oncogenic dysregulation driving liver cancer pathogenesis remain incompletely understood. Lymphotoxin-β receptor (LTβR) signalling is critically involved in hepatitis and liver tumorigenesis. Therefore, we explored the interdependence of inflammatory lymphotoxin signalling and specific oncogenic pathways in the progression of hepatic cancer. DESIGN: Pathologically distinct liver tumours were initiated by hydrodynamic transfection of oncogenic V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT)/β-catenin or AKT/Notch expressing plasmids. To investigate the relationship of LTβR signalling and specific oncogenic pathways, LTβR antagonist (LTβR-Fc) or agonist (anti-LTβR) were administered post oncogene transfection. Initiated livers/tumours were investigated for changes in oncogene expression, tumour proliferation, progression, latency and pathology. Moreover, specific LTβR-mediated molecular events were investigated in human liver cancer cell lines and through transcriptional analyses of samples from patients with intrahepatic cholangiocarcinoma (ICC). RESULTS: AKT/β-catenin-transfected livers displayed increased expression of LTβ and LTβR, with antagonism of LTβR signalling reducing tumour progression and enhancing survival. Conversely, enforced LTβR-activation of AKT/β-catenin-initiated tumours induced robust increases in proliferation and progression of hepatic tumour phenotypes in an AKT-dependent manner. LTβR-activation also rapidly accelerated ICC progression initiated by AKT/Notch, but not Notch alone. Moreover, LTβR-accelerated development coincides with increases of Notch, Hes1, c-MYC, pAKT and β-catenin. We further demonstrate LTβR signalling in human liver cancer cell lines to be a regulator of Notch, pAKT(ser473) and β-catenin. Transcriptome analysis of samples from patients with ICC links increased LTβR network expression with poor patient survival, increased Notch1 expression and Notch and AKT/PI3K signalling. CONCLUSIONS: Our findings link LTβR and oncogenic AKT signalling in the development of ICC.
format Online
Article
Text
id pubmed-5036232
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50362322016-10-17 LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours Scarzello, Anthony J Jiang, Qun Back, Timothy Dang, Hien Hodge, Deborah Hanson, Charlotte Subleski, Jeffrey Weiss, Jonathan M Stauffer, Jimmy K Chaisaingmongkol, Jitti Rabibhadana, Siritida Ruchirawat, Mathuros Ortaldo, John Wang, Xin Wei Norris, Paula S Ware, Carl F Wiltrout, Robert H Gut Hepatology OBJECTIVES: The relative contributions of inflammatory signalling and sequential oncogenic dysregulation driving liver cancer pathogenesis remain incompletely understood. Lymphotoxin-β receptor (LTβR) signalling is critically involved in hepatitis and liver tumorigenesis. Therefore, we explored the interdependence of inflammatory lymphotoxin signalling and specific oncogenic pathways in the progression of hepatic cancer. DESIGN: Pathologically distinct liver tumours were initiated by hydrodynamic transfection of oncogenic V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT)/β-catenin or AKT/Notch expressing plasmids. To investigate the relationship of LTβR signalling and specific oncogenic pathways, LTβR antagonist (LTβR-Fc) or agonist (anti-LTβR) were administered post oncogene transfection. Initiated livers/tumours were investigated for changes in oncogene expression, tumour proliferation, progression, latency and pathology. Moreover, specific LTβR-mediated molecular events were investigated in human liver cancer cell lines and through transcriptional analyses of samples from patients with intrahepatic cholangiocarcinoma (ICC). RESULTS: AKT/β-catenin-transfected livers displayed increased expression of LTβ and LTβR, with antagonism of LTβR signalling reducing tumour progression and enhancing survival. Conversely, enforced LTβR-activation of AKT/β-catenin-initiated tumours induced robust increases in proliferation and progression of hepatic tumour phenotypes in an AKT-dependent manner. LTβR-activation also rapidly accelerated ICC progression initiated by AKT/Notch, but not Notch alone. Moreover, LTβR-accelerated development coincides with increases of Notch, Hes1, c-MYC, pAKT and β-catenin. We further demonstrate LTβR signalling in human liver cancer cell lines to be a regulator of Notch, pAKT(ser473) and β-catenin. Transcriptome analysis of samples from patients with ICC links increased LTβR network expression with poor patient survival, increased Notch1 expression and Notch and AKT/PI3K signalling. CONCLUSIONS: Our findings link LTβR and oncogenic AKT signalling in the development of ICC. BMJ Publishing Group 2016-10 2015-07-23 /pmc/articles/PMC5036232/ /pubmed/26206664 http://dx.doi.org/10.1136/gutjnl-2014-308810 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Hepatology
Scarzello, Anthony J
Jiang, Qun
Back, Timothy
Dang, Hien
Hodge, Deborah
Hanson, Charlotte
Subleski, Jeffrey
Weiss, Jonathan M
Stauffer, Jimmy K
Chaisaingmongkol, Jitti
Rabibhadana, Siritida
Ruchirawat, Mathuros
Ortaldo, John
Wang, Xin Wei
Norris, Paula S
Ware, Carl F
Wiltrout, Robert H
LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
title LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
title_full LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
title_fullStr LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
title_full_unstemmed LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
title_short LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours
title_sort ltβr signalling preferentially accelerates oncogenic akt-initiated liver tumours
topic Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036232/
https://www.ncbi.nlm.nih.gov/pubmed/26206664
http://dx.doi.org/10.1136/gutjnl-2014-308810
work_keys_str_mv AT scarzelloanthonyj ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT jiangqun ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT backtimothy ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT danghien ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT hodgedeborah ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT hansoncharlotte ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT subleskijeffrey ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT weissjonathanm ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT staufferjimmyk ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT chaisaingmongkoljitti ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT rabibhadanasiritida ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT ruchirawatmathuros ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT ortaldojohn ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT wangxinwei ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT norrispaulas ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT warecarlf ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours
AT wiltroutroberth ltbrsignallingpreferentiallyacceleratesoncogenicaktinitiatedlivertumours